Representative experience
Defended a global accounting firm in a ’34 Act class action alleging failure to discover a client fraudulently concealed true financial condition.
Defended a biotech company in a ’33 Act class action alleging a subsidiary misled investors by failing to disclose core products declining sales.
Defended the CEO of a major sporting goods manufacturer: ’34 Act class action alleged failure to disclose negative impact on revenue/profit margins.
Defended an infrastructure engineering and construction company: ’34 Act class action alleged false fiscal performance and estimate fee claims.
Defended a commercial-stage pharmaceutical company: ’34 Act class action alleged false claims on efficacy, results, and likely market for its drug.
Defended a pharmaceutical company and its officers: ’34 Act class action alleged false claims regarding product efficacy and clinical trial results.
Defended a manufacturing CEO in a US$20 billion securities fraud class action alleging misleading statements about its product demand and accounting.
Defended a clinical stage pharmaceutical company: ’34 Act class action alleged misrepresentation regarding FDA approval for a new drug application.
Defended a financial institution in a ’34 Act class action alleging the bank failed to accurately report its allowance for loan and lease losses.
Defended former officers of an energy company in a ’34 Act case alleging the executives concealed the company’s deteriorating financial condition.
Defended a communications company: shareholder derivative action asserting breach of fiduciary duty by introducing certain subscription TV offers.
Defended a bank: shareholder derivative action alleged breach of fiduciary duty to a subsidiary by stopping an IPO and accelerating loan repayment.
Defended a Cayman Island hedge fund in a shareholder derivative action alleging the management entity misled investors and wasted corporate assets.
Defended a Maryland-based mortgage REIT: multidistrict shareholder derivative suit challenged internalizing REIT’s past external manager and fees.
Defended a Delaware bio-tech corporation in multidistrict shareholder litigation challenging a proposed merger.
Defended a public aerospace and defense industry company dispute; joint-venture partner alleged breaches with aiding and abetting of fiduciary duty.
Defended a healthcare company in a post-acquisition dispute regarding a US$100 million post-closing price adjustment dispute.
